Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioning itself at the intersection of artificial intelligence and precision medicine, aiming to improve early detection and diagnosis of coronary heart disease. The company’s blood-based tests, Epi+Gen CHD and PrecisionCHD, leverage a proprietary AI-driven Multi-Omics Engine that analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including certain nonobstructive forms that conventional diagnostic methods may miss. This approach addresses a cardiovascular disease market projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050.
Cardio Diagnostics has strengthened its commercialization efforts through securing finalized CMS reimbursement rates and dedicated CPT laboratory codes. The company is expanding U.S. provider partnerships and has launched its first international expansion in India. With a proprietary AI-driven platform, reimbursement milestones, growing provider adoption, and evidence supporting its ability to detect what traditional tools miss, the company occupies a position that is scientifically grounded and commercially actionable in the diagnostics landscape.
For more information, visit the company’s newsroom at https://nnw.fm/CDIO and the full article at https://nnw.fm/9LJ2r.
